Long-term nitrofurantoin: an analysis of complication awareness, monitoring, and pulmonary injury cases

Toby Peter Speirs; Nicole Tuffin; Finlay Mundy-Baird; Helena Sakota; Sarah Mulholland; Michelle Westlake; Max Lyon; Andrew R Medford; Charles Sharp; Michael Darby; Mahableshwar Albur; Francis Keeley; Helena Burden; Charlie Kenward; Elizabeth Jonas; Shaney Barratt; Huzaifa I Adamali

doi:10.3399/BJGPO.2021.0083

Submit a Response to This Article

Compose eLetter

Title *

Author Information

Contributors

First Name and Middle Initial *

First or given name, e.g. 'Peter'.

Last Name *

Your last, or family, name, e.g. 'MacMoody'.

Email Address *

Your email address, e.g. higgs-boson@gmail.com. PLEASE NOTE: your email address will be published.

Occupation *

Your role and/or occupation, e.g. 'Orthopedic Surgeon'.

Affiliation *

Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Jump to comment:

RE: Long-term nitrofurantoin – an ongoing safety problem
Will Howe, Ronan Sheehan, Marco Motta and Mike Wilcock

Published on: 15 September 2021

Published on: (15 September 2021)
Page navigation anchor for RE: Long-term nitrofurantoin – an ongoing safety problem
RE: Long-term nitrofurantoin – an ongoing safety problem
Will Howe, GP, Lostwithiel Surgery, Cornwall
Other Contributors:
Ronan Sheehan, Clinical Pharmacist

Marco Motta, Pharmacist

Mike Wilcock, Pharmacist
Dear Sir
We note with interest the research undertaken by Speirs et al identifying a lack of awareness amongst prescribers of serious adverse effects that can occur with long-term nitrofurantoin and the need for more robust monitoring guidelines. As a result of discussions on the potential safety risk of long-term nitrofurantoin and known medico-legal implications,(1,2) we examined the monitoring schedule for nitrofurantoin across a convenience sample of ten practices in two of our primary care networks.

The computer records of patients that had a record of being prescribed nitrofurantoin (15 or more tablets) were searched over one month in early 2021. From a total registered population of approximately 86,000 patients, we identified 41 patients (35 female) who had received a prescription for prophylactic nitrofurantoin. Thirty-two (78%) of this cohort were aged over 65 years.

In only 8 (20%) instances was there any evidence in the GP records of a discussion with the patient about possible adverse effects. Liver function had been monitored in 22 (54%) patients within 6 months, whilst a respiratory review had occurred for only 5 (12%) patients, though such a review had been triggered by suspicion of a newly presenting pulmonary complication.

Nitrofurantoin is commonly used for the treatment and prophylaxis of recurrent urinary tract infections (UTIs), and typically any such prescription is commenced by a GP, though such a decision may also be made...
Show More

Dear Sir
We note with interest the research undertaken by Speirs et al identifying a lack of awareness amongst prescribers of serious adverse effects that can occur with long-term nitrofurantoin and the need for more robust monitoring guidelines. As a result of discussions on the potential safety risk of long-term nitrofurantoin and known medico-legal implications,(1,2) we examined the monitoring schedule for nitrofurantoin across a convenience sample of ten practices in two of our primary care networks.

The computer records of patients that had a record of being prescribed nitrofurantoin (15 or more tablets) were searched over one month in early 2021. From a total registered population of approximately 86,000 patients, we identified 41 patients (35 female) who had received a prescription for prophylactic nitrofurantoin. Thirty-two (78%) of this cohort were aged over 65 years.

In only 8 (20%) instances was there any evidence in the GP records of a discussion with the patient about possible adverse effects. Liver function had been monitored in 22 (54%) patients within 6 months, whilst a respiratory review had occurred for only 5 (12%) patients, though such a review had been triggered by suspicion of a newly presenting pulmonary complication.

Nitrofurantoin is commonly used for the treatment and prophylaxis of recurrent urinary tract infections (UTIs), and typically any such prescription is commenced by a GP, though such a decision may also be made following advice from a urology specialist. Standard prescribing advice is that at commencement of prophylaxis there should be discussion with the patient of the risks of long-term antibiotics including resistance and possible adverse effects, and monitoring (liver function and for signs of pulmonary adverse effects, especially in the elderly) is advised for long-term therapy.(3) Our small study, albeit with no follow up of patient outcomes, points to some deficiencies in following this advice.

We echo the call by Speirs et al for augmentation of current guidelines with a model monitoring plan.

Yours sincerely

Will Howe, GP, Lostwithiel Surgery, Cornwall
Ronan Sheehan, Clinical Pharmacist, Three Harbours and Bosvena Health PCN, Cornwall
Marco Motta, Pharmacist, NHS Kernow CCG Medicines Optimisation Team, Cornwall
Mike Wilcock, Pharmacist, Royal Cornwall Hospitals NHS Trust, Cornwall

References
1. https://www.medicalprotection.org/uk/articles/complications-of-nitrofura...
2. https://www.medicalprotection.org/uk/articles/nitrofurantoin-complicatio...
3. https://cks.nice.org.uk/topics/urinary-tract-infection-lower-women/manag...
Show Less

Competing Interests: None declared.